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Abstract
Personalized medicine and targeted therapy have been emerging fields of study for the
remediation and inhibition of cancer. Personalized medicine in the treatment of cancer involves
using genetic, immune, and proteomic profiling to provide therapeutic options as well as
prognostic background for every patient and their tumor’s genetic mutations. Targeted therapies
allow researchers and medical personnel alike to determine the appropriate treatment for a patient
based on the molecular basis and mechanistic actions of a cancerous tumor. The overall
significance of this study was to express how these treatments use biomarkers to pinpoint the
location, and severity of the cancer, and to administer the right treatment. Early detection of tumor‐
specific biomarkers can allow the use of non‐invasive routine monitoring.
The study aims to provide an elaborate explanation on the various biomarker classification
and present the protocol on how they are sorted and validated to be a potential cancer biomarker
used in clinical practice. Categorizing biomarkers relies on their characteristics. These classifiers
will divide them into one of the following groups: general biomarkers, DNA biomarkers, and DNA
tumor biomarker. The expressions of microRNA also play a role in the determination of cancer,
as most of these clusters regulate the expression and transcriptional activity of various cancer cell
lines. The expression of the ER receptors in mammalian cells classifies breast cancer into one of
the following categories: triple negative, estrogen receptor (ER) negative, or (ER) positive. ER
positive breast cancer patients can positively benefit from personalized medicine as these patients
have to undergo specific hormonal therapy and supplementary adjuvant chemotherapy to eliminate
the estrogen-induced proliferation of these mammalian cells. Drugs like tamoxifen function as
antagonists to the ER receptor to inhibit the transcriptional activity of the ER receptors. Other
cancer types such as colorectal cancer, and lung cancer may also benefit from such approaches.
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The limitations of the study include the unique genomic profiling of each patient,
challenges in validation and implementation of drug combinations, and the deployment of
technologies for DNA sequencing.
Keywords: cancer, biomarkers, personalized medicine, gene therapy, targeted therapy,
DNA Biomarker, RNA expressions, ER, colorectal cancer, lung cancer, prostate cancer, leukemia,
targeted treatment

I. Introduction to Personalized Medicine, Biomarkers, and Targeted Treatment
The release of the first draft of the Human Genome Project (Collins et al., 2002) has
allowed scientists and researchers to make much progress in the field of clinical medicine through
the discovery of multiple genes. Scientists believe that these genes contribute to the growth and
progression of various human illnesses. The Human Genome Project aims to progress the
development of personalized medicine, which is an emerging path in the field of healthcare
(Collins et al., 2003). Personalized medicine is an evidence-based approach for treating patient
health concerns (Chan & Ginsberg, 2011). This approach analyzes the molecular mechanisms
involved in the progression and development of the disease to enhance existing health strategies
or to develop novel preventive health care measures (Hua et al., 2018). Its goal is to individualize
patient care while offering the maximum medical care possible to remediate, and ultimately inhibit,
the development of disease. The emergence of personalized medicine has been a promising
movement to provide a more effective treatment for progressive diseases. The standard treatments,
that are currently available, are quite invasive and limited (Chan & Ginsberg, 2011). Diseases
situated in an inaccessible body part, or diseases in more advanced stages, may render treatments,
such as chemotherapy, as inadequate to inhibit the proliferation of the disease. “Typical current
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intervention” dictates treatments and its detection, it is costly to treat with low reversibility
probabilities (Chan & Ginsburg, 2011). Novel genome-based drug formulations targeting specific
biomarkers are emerging alternatives to general treatments. This formulation can help researchers
and clinicians identify the disease and its baseline risks, since diagnostic biomarkers are invariant
during disease progression and permit diagnosis in its early stages, thus lowering the cost and risks
for the patient (Jain, 2002; Biomarkers Definitions Working Group, 2001).

Figure 1. The application of genome-based technologies as personalized health care measures
(taken from Chan & Ginsburg, 2011)
The developments in the field of genomics have allowed scientists and researchers to
pinpoint specific molecular events which lead to a progressive disease like cancer. These
molecular events in the human body are chromosomal rearrangements, gene amplifications, and
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other DNA mutations (Leary et al., 2010). These alterations at the genomic level are avoidable by
the formulation of novel anti-cancer drugs, and the implementation of tailor-fitted adjuvant therapy
to locate the prominent gene expression signatures created by a specific disease. Gene expression
signatures can serve as biomarkers, which are biological molecules that function as indicators of
body responses (Guo et al., 2016). Biomarkers are biological substances that are measured in the
body and may affect the prediction and interpretation of any sickness outcomes (Ganesalingam &
Bowser, 2010).
II. Overview of Various Cancer Related Biomarkers
A. Categories of Biomarkers
Biomarkers are useful in personalized medicine by providing better prognostic and
predictive markers in comparison to the typical intervention processes (Hamburg & Collins, 2010).
This advantage makes it easier for clinicians to provide a better treatment plan for patients.
Biomarkers are classified into three distinct classifications: DNA biomarkers, DNA tumor
biomarkers, and general biomarkers (Kamel et al., 2017). The discovery of new prognostic and
predictive biomarkers drives the paradigm for the exploitation of genomic-based technologies in
personalized medicine. Biomarkers are important for monitoring drug responses and deciding
which patients will effectively respond to treatments. (Jariyal et al., 2020).
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Figure 2. The paradigm for the exploitation of genomic-based technologies in personalized
medicine (taken from Kamel et al., 2017).

A.1. DNA Biomarkers
The genetic information coded in the DNA should be stable since the DNA directs the
protein synthesis needed for a proper cellular structure and function. DNA biomarkers are small,
but distinct, sequence level variations of DNA, which include base pair insertions, deletions, single
nucleotide polymorphisms (SNPs) and short tandem repeats (STRs) (Kamel et al., 2017). SNPs
are a very common type of DNA biomarker due to the availability of high-throughput sequencing
technologies and biological facilities. In addition, SNPs are diallelic in most applications yielding
three possible genotypic combinations, which are indicators of epigenetic changes comprised of
histone modifications and DNA methylation.
An important consideration about these biomarkers is their stability in comparison with
DNA tumor and general biomarkers. Their stability enables the storing of samples for longer
periods of time. In addition, DNA biomarkers are reproducible, which deems advantageous in both
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prospective and retrospective studies. Furthermore, these biomarkers have simpler storage and
handling protocols, which yields a lower cost compared to the other biomarker types. However,
DNA biomarkers cannot be of use for therapy monitoring and pharmacodynamics since the
alterations made during the initiation of the disease remain the same throughout the advancement
and proliferation of the disease (Ganesalingam & Bowser, 2010).
A.2. DNA Tumor Biomarkers
DNA tumor biomarkers, on the other hand, are rearrangement-associated biomarkers
specific to a cancerous tumor. Such alterations are present in the early stages of tumor formation
and continue throughout tumor development. These tumor-specific chromosomal alterations can
be specific biomarkers for tumor detection, since they are unique in cancerous cells and are absent
in normal and healthy cells. Examples of these recurrent somatic alterations in hematopoietic
malignancies usually include the following oncogenic genes: BCR-ABL fusion oncogene, T cell
receptor genes, retinoic acid receptor α genes, and immunoglobulin genes (Leary et al., 2010).

A.3. Predictive Biomarkers
Predictive biomarkers provide data about the possible and expected responses to a certain
therapy. The biomarkers can provide a plan for a specific treatment. Predictive biomarkers are an
anticipation of possible responses the body of the patient will have to the given treatment and how
they can affect or improve it. These biomarkers guide the customized treatment plan for patients
while getting more information about the malignancy and behavior of the tumor in analysis.
Predictive biomarkers are sometimes shared between various tumor types. These predictive
biomarkers might be of use in dose determination and selection studies as well as in response
measurements of new biological agents. Examples of highly studied DNA biomarkers are the

Published by NSUWorks, 2020

7

Mako: NSU Undergraduate Student Journal, Vol. 2020 [2020], Art. 1

mutations in gene protein encoders responsible for DNA damage repair. Oncogenes such as the
breast cancer gene 1 (BRCA1), and the breast cancer gene 2 (BRCA2) can increase the risk of
patients for breast cancer. Some common predictive biomarkers for selected cancers are
summarized in Table 1.

Table 1. Summary of predictive biomarkers for selected cancers (taken from Kamel et al., 2017).
Cancer

Biomarker Clinical utility and significance

Breast
cancer

PR

High PR expression predicting beneficial response to tamoxifen
therapy

ER

High Cellular ER expression predicting benefit from tamoxifenbased chemotherapy in node-negative patients

BRCA1

High BRCA1 expression predicting response to chemotherapy

HER2

Overexpression of HER2 predicting response to treatment with
trastuzumab

AKT
kinase
isoform

Akt kinase isoforms and activity predicting response to
trastuzumab-based therapy in HER2-positive metastatic cancer
patients

LOH at
18q

Predicting benefit from 5-FU based adjuvant chemotherapy

EGFR1

EGFR1 amplification predicting response to anti-EGFR1 antibody
therapy

KRAS

KRAS mutation negatively predicting benefit from EGFR-targeted
therapy

BRCA1

High BRCA1 expression predicting resistance to chemotherapy

TP53

High TP53 expression predicting sensitivity to cisplatin; TP53
mutations predicting resistance to cisplatin

Colorectal
cancer

Non-small
cell lung
cancer
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KRAS

KRAS mutation predicting lack of response to adjuvant
chemotherapy in early disease and resistance to treatment with
EGFR-targeted or TKI in advanced disease

III. Discussion
A. The Role of MicroRNA Expressions in Cancer
Molecular biology provides the technology to develop and identify biomarkers, which are
used in therapies such as RNA/DNA microarray tests that help to rationalize and personalize
treatment plans (Crommelin, 2011). MicroRNA (miRNA) expression is a gene expression which
has received much attention from researchers not because of its great advancement in scientific
knowledge, but because they can be adjusted and used in many types of cancer as they are a gene
expression that has a direct relation and interaction with the tumor causing the cancer (Mathe et
al., 2017). MicroRNAs are fragments of small non-coding RNA that work to regulate gene
expression at translational or post-transcriptional levels. MicroRNAs have important interactions
with specific oncogenes in various types of cancers. For example, the development of a lymphoma
is induced by miR-17, miR-20, and miR-92 microRNA clusters (Mathe et al., 2017). In addition,
the overexpression of miR-106a is linked with the downregulation of RB1, a tumor suppressor, in
lung, gastric, and prostate cancers (Kamel et al., 2017). MicroRNA’s regulate the expression of
both the ERα and ERβ receptors. The expression, transcriptional activity, proliferative action of
ERα, and the tumor-suppressor properties of ERβ affect the carcinogenic activity of estrogen that
usually develops into breast cancer. In ERα-negative cancer cells, the expression of the miRNA206 increases, which targets the ERα mRNA 3’-untranslated regions (3’-UTR) inhibiting its
expression. The microRNA, miR-27a, also inhibits ERα transcription by targeting the repressor of
a specificity protein, ZBTB10, which regulates ERα expression (Mathe et al., 2015).
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B. Targeted Gene Therapies for Cancer
B.1. Breast Cancer
Breast cancer is classified into four distinct classes based on the profiling of its gene
expressions defined by a class of known molecular biomarkers (Sommer, 2001). The classification
is summarized in Table 2. Breast cancer is the resulting of carcinogenic activity of estrogen (i.e.,
estrone, estradiol, and estriol) induced by the proliferative action of ERα through transcription,
and by the tumor-suppressor properties of ERβ (Guiu et al., 2009; Perou et al., 2009; Sotiriou &
Pusztai, 2009). One of the biological effects of estrogen is the mediation of both the binding and
activation of the ERα and ERβ receptors. The ERα and ERβ receptors are classified under the
superfamily of nuclear receptor transcription factors, which are classified by its DNA- and ligandbinding domains (Duong et al., 2006).

Table 2. Types of breast cancer based on gene expression profiling (taken from Kamel et al.,
2017).
Classification

Classification

Luminal-A

Estrogen receptor positive, low histological grade

Luminal-B

Estrogen receptor positive, high histological grade

Basal-Like

Estrogen receptor negative, progesterone receptor negative, and human
epidermal growth factor receptor 2 (HER2) negative

HER2-Like

HER-2 positive and overexpresses erb B-2
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Both Luminal-A and Luminal-B cancer show to have an increased expression and
elevated levels of genetic biomarkers like those found in the normal breast myoepithelial cells (i.e.,
luminal cytokeratin). The proliferation of mammary cells induced by estrogen resulting to
overexpression, disruption of cell cycle, and cell apoptosis is what characterizes ER-positive breast
cancers. ER-positive breast cancers comprise around 80% of the total breast cancer cases.
Hormonal therapy helps patients to inhibit the proliferation of cancer cells.
Breast cancer falls into classification of one of five molecular classes. 1, and 2 are luminal
A and luminal B (hormone receptor positive). 3 is HER2-positive, a human epidermal growth
factor receptor-2. Category 4 is basal-like and normal-like based on microarray and gene
expression profiling and 5 claudin-low, triple-negative breast cancer, which includes medullary
and metaplastic differentiation (Jeibouei et al., 2019).

Figure 3. The estrogen-positive and estrogen-negative breast cancer
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(taken from the National Cancer Institute, 2020).

An example of a drug administered under endocrine therapy for this type of cancer
includes tamoxifen, a selective estrogen receptor modulator, which functions as an antagonist to
inhibit the transcriptional activity of the ER receptors (American Cancer Society, 2020).
Tamoxifen, a drug commonly used for hormone-positive breast cancer, blocks estrogen attachment
to the ER receptors that dampen, or ultimate stop the cancer cell growth (National Cancer Institute,
2020; Sneha & Doss, 2016).

Figure 4. Chemical structure of tamoxifen. (Taken from Valny et al., 2016)
The basal-type cancers, on the other hand, do not overexpress the above-mentioned genes,
but they correlate with other biomarkers like cytokeratin 5, epidermal growth factor (EGF),
hepatocyte growth factor (HGF), insulin growth factor (IGF)receptors. Statistics show that most
breast cancers induced by BRCA1 mutations were of basal-like cancer classification (Kamel et al.,
2017).
The ligand-induced activation of the ER receptor starts with the binding of the agonists
to the ER complex which induces a series of conformational changes in the receptor leading to the
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dissociation of the chaperone protein, the heat shock protein 90 (hsp90), and the dimerization of
the ER complex. The co-activator complex then binds to the dimerized receptor, which allows it
to interact with the target DNA sequence. Then, the basal transcription factors interact with the
attached co-activator complex which stimulates the acetylation of histones and the initiation of the
transcription of the target gene. Histone modification reactions prior to transcription are necessary
to transform the tightly coiled chromatin into a loose, and transcriptionally active structure. In
addition, histone acetylation is an essential part of the ER activation process as histone deacetylase
(HDAC) inhibitors can restore the transcriptional activity of the ERα receptor in ERα-negative
breast cancer cells. In addition, HDAC inhibitors, as well as various available demethylating
agents, serve as an effective treatment for ERα-negative breast cancer patients to induce the
expression of the ERα receptor (Ogryzko et al., 1996). The entire transcription process of the ERα
gene generates a 4.3 kb long mRNA sequence, which contains the 3’-UTR. This untranslated
region contains various regulatory elements that may direct mRNA destabilization (Sommer,
2001).
The antagonist-induced inhibition of the ER receptor, on the other hand, starts with the
binding of the antagonist to the ER complex leading to the conformational changes distinct to those
found in agonist binding, the dissociation of the hsp90 protein, and the dimerization of the ER
complex (Sommer, 2001). The co-suppressor complex then binds to the dimerized receptor, which
allows it to interact with the target DNA sequence. However, DNA binding does not recruit all the
basal transcription factors leading to the inhibition of the transcription process (Sommer, 2001).
Lastly, the co-suppressor complex deacetylates the histones through the action of HDAC, which
prohibits the binding of the transcription factors into the tightly wrapped DNA around the histone
cores (Sommer, 2001).
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Figure 5. A simplified model of the agonist-induced stimulation and antagonist-induced
inhibition of the ER-regulated gene transcription (Taken from Sommer, 2001).

B.2. Colorectal Cancer
Up to this date, there is a scarcity in information about the molecular alterations and gene
translocations associated with colorectal cancer. Studies have shown that the progression of this
type of cancer involves mutations of the genes that encode the Kirsten rat sarcoma (KRAS) viral
oncogene, adenomatous polyposis coli (APC) protein, and the P53 or TP53 tumor protein. In
addition, gene expression profiling studies have shown that the 23-gene signature can be a potential
predictor for the recurrence of colorectal cancer amongst patients. These findings may help future
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researchers in formulating appropriate gene therapies for colorectal cancer patients (Kamel et al.,
2017).

B.3. Prostate Cancer
Prostate cancer is one of the leading causes of mortality in men. Even if treatment seems
to cure the cancer in its early stages, up to 50% of patients regress after initial therapy (Kafka et
al., 2020). Studies show that the initiation and proliferation of prostate cancer cells catalyze from
the deletion of the phosphatase and tensin homolog on chromosome 10 (PTEN), which is an
essential gene responsible for tumor suppression. The translocation of the genes that encode the
E-twenty-six specific related gene (ERG) and the serine 2 (TMPRSS2) transmembrane protease
also contributes to the advancement of prostate cancer (Kamel et al., 2017).

B.4. Lung Cancer
In lung cancer there is a 5-gene and 12-gene signature gene expression pattern that
correlates with the recurrence of lung cancer among patients after treatment. The 12-gene signature
is used to classify patients according to susceptibility to adjuvant chemotherapy (Kamel et al.,
2017). A variety of lung cancer biomarkers help to dictate therapy, such as targeting tumor growth
by specific drug therapies (EGFR, ALK, ROS1, HER2, BRAF/MEK, MET, and RET mutation
and aberrancies) (Sears et al., 2020)

C. Targeted Drug Therapy and Specific Gene Targets: HER2 and EGFR genes
The aim of personalized medicine and targeted drug therapy is to provide a customized
treatment plan for patients according to the molecular profiles and signature expression of tumor
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tissues. Trastuzumab is a monoclonal antibody used as an adjuvant therapy for HER2-positive
metastatic breast cancer patients (Hurvitz et al., 2013). It induces the downregulation of the HER2
gene which is overexpressed in the early stages of the breast cancer. It also acts as a tyrosine kinase
inhibitor in colorectal cancer and chronic myelogenous leukemia patients. In addition, trastuzumab
inhibits the expression of the EGFR gene in EGFR mutation induced lung cancer. Lapatinib, on
the other hand, is a drug that targets the HER2 and possesses a high affinity for the EGFR gene,
specifically in the EGFR1 intracellular domains (Hurvitz et al., 2013; Kamel et al., 2017). It is also
a tyrosine kinase inhibitor that, in conjunction with trastuzumab, remediates the progression of the
invasive HER2-positive breast cancer. Other drugs and targeted therapies for selected types of
cancer are summarized in Table 3, Figure 3, and Appendices A-C.

Table 3. Summary of targeted therapies for selected types of cancers (taken from Kamel et al.,
2017).
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Figure 6. Body map of the available markers and targeted therapies for cancer
(taken from Kamel et al., 2017).
Amidst all the advantages presented on personalized medicine, this emerging field also has
a list of limitations which can be source of future potential research to further the knowledge on
cancer and how it can be treated. Such limitations include the unique genomic profiling of each
patient. These small mutations in the genomic sequence can drive the development of medication
in cohorts based on the frequency of these genomic alterations. In addition, challenges in validation
and implementation of drug combinations, as well the deployment of technologies for DNA
sequencing can limit the scope of the study. Further research needs to probe on the development
of advance genomic algorithms which can implement high accurate and reliable software that can
be used for personalized medicine.
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IV. Conclusion
Personalized medicine is a futuristic and potentially idealistic system to help every patient
seek for and obtain urgent, specialized attention. It could change the approach to medicine, as well
as the attention given to a patient with cancer, specifically attending to the issues the person is
presenting and the cancerous cells the patient has in the respective body part. Biomarkers in the
therapy for cancer patients could be a helpful tool to provide an on-time prognosis and treatment
of the disease. It is also a futuristic plan that cancer patients should have the option to consider.
Targeted therapy could also be a transformative change in medical attention, as the use of
biomarkers in this therapy can identify the specific type of therapy the patient needs.

V. Appendix:
A. Drug & Gene Table
This table covers 38 drugs undergoing study as gene treatment for 5 different cancers:
Breast cancer, colorectal cancer, leukemia, non-small cell lung cancer, and prostate cancer.
These drugs for targeted gene therapy were chosen from the National Cancer Institute,
2020.
With these 38 drugs, 17 genes are being targeted for treatment to solve the issue within the
gene, causing cancer. They are classified into 13 different types of molecules. To determine
which drug would be used for treatment, it should first be determined which gene has gone
wrong. From there, a drug that treats the issue of that gene can be decided on.
B. Animated Flowcharts
These flowcharts are simple visual depictions of the drug & gene table spreadsheet located
in Appendix A. Each section is separated by cancer type, further branching into the
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applicable treatments. Drugs that share a common gene target are grouped together. The
flowchart gives more detail about each oncogene: the type of molecule, which chromosome
it is located on, the issue leading to cancer, and the gene’s function.
C. Illustrations
These illustrations explain targeted cancer treatments in a simplified way.
Image 1: The switching of pre-cancerous proto-oncogenes into cancerous Oncogenes.
This image shows genes forcibly turning on the cancer switch, due to the function of
oncogenes.
Image 2: Ways that the expression of some key oncogenes can be lessened.
This image conveys a group of oncogenes seeking therapy to treat their abnormalities.
Image 3: Learning about different drugs for treating specific oncogenes.
This illustration describes the specific treatment for the abnormality in the gene, mTOR,
and prescribes specialized drug treatment.
Image 4: Diagnosing a specific gene abnormality and prescribing treatment.
In this image, Gleevec is prescribed to treat the abnormality in the gene, BCR-ABL1.
The abnormality can lead to Leukemia, and Gleevec treats it by inhibiting protein kinase.
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